Objective: To analyze the clinical feature and the value of chemotherapy for advanced stage bronchioloalveolar carcinoma (BAC) of the lung.
Methods: The clinical data of 53 advanced stage BAC patients treated from Jan. 1999 to Dec. 2004 was collected and reviewed. Most of the patients received more than 2 cycles of the combined chemotherapy with platinum-based regimen.
Results: Of these 53 eligible patients in this series, 34 (64.2%) were women, 42 (79.2%) never smoked any cigarette, 29 (54.7%) originated from the right lung, and 12 patients (22.6%) showed bilateral multi-lobular or multi-central lesions or diffusive pulmonary involvement. The objective response rate was 17.0% (2 complete response, 7 partial response). 30 (56.6%) patients demonstrated stable disease and 14 (26.4%) patients showed progression of the disease. The median progression-free and overall survivals were 6.1 and 16.0 months, respectively. The 1-year survival rate was 71.7%. Grade 3 or severer toxicities included neutropenia (34.0%), thrombocytopenia (15.1%), anemia (22.6%), nausea and vomiting (39.6%), alopecia (30.2%), constipation (17.0%) and peripheral neurotoxicity (13.2%).
Conclusion: Advanced bronchioloalveolar carcinoma is likely to occur in woman, nonsmoker and the right lung, frequently with bilateral diffuse pulmonary involvement. The platinum-based combined chemotherapy regimen is modestly effective with tolerable toxicity. Compared with the historical data of lung adenocarcinoma of the same stage, bronchioloalveolar carcinoma has a longer overall survived.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma).
Ther Adv Med Oncol
November 2024
Medical College of Wisconsin, MCW Cancer Center/Administrative Office, 9200 West Wisconsin Avenue, Suite C5300, Milwaukee, WI 53226, USA.
Background: Anti-programmed death-1 (PD-1)/cytotoxic T lymphocyte antigen-4 antibodies are efficacious in various malignancies.
Objectives: This study presents the first results of ipilimumab-nivolumab in invasive mucinous or non-mucinous lepidic adenocarcinoma (invasive mucinous adenocarcinoma (IMA) or invasive non-mucinous lepidic adenocarcinomas (INLA), respectively) of the lung.
Design: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) is a prospective, open-label, multicenter (1016 US sites), multi-cohort phase II trial of ipilimumab (1 mg/kg intravenously (IV) every 6 weeks) plus nivolumab (240 mg IV every 2 weeks).
Bilateral orthotopic lung transplantation for the patient with lung-limited invasive mucinous adenocarcinoma: a case-based literature review.
Oncologist
November 2024
Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Article Synopsis
- - Invasive mucinous adenocarcinoma (IMA) of the lung has unique features such as multicentric lesions and low distant metastasis but a poor prognosis, with median survival under a year.
- - While treatment options are limited, lung transplantation in selected IMA patients has shown improved survival, but with high rates of recurrence often linked to the primary tumor.
- - A notable case of bilateral lung transplantation using cardiopulmonary bypass for stage ⅣA lung-limited IMA achieved 15 months of stable health without disease recurrence or organ rejection, and IMA's characteristics and outcomes are discussed in relation to prior classifications and other lung transplantation cases.
Lipid Pneumonia Mimicking Lung Cancer in a Middle-Age Woman.
Ann Thorac Cardiovasc Surg
October 2024
Department of Thoracic Surgery, MacKay Memorial Hospital, Taipei, Taiwan.
Lipid pneumonia is exceedingly rare, with only a few reported cases to date. A 46-year-old woman with a history of left breast cancer underwent a left-modified radical mastectomy, adjuvant chemotherapy, and radiotherapy. Despite no known exposure to lipids, she presented with chronic non-productive cough and general malaise.
View Article and Find Full Text PDFFullerene and fullerene whisker are not carcinogenic to the lungs and pleura in rat long-term study after 2-week intra-tracheal intrapulmonary administration.
Arch Toxicol
December 2024
Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, 467-8601, Japan.
Article Synopsis
- - Fullerene whiskers (FLWs) and fullerenes (FLs) are rod-like structures made of carbon, and their shape raises concerns about potential health risks similar to those posed by asbestos and carbon nanotubes, but no long-term studies on their carcinogenic effects have been conducted.
- - In a study, male rats were given FL, FLW, and different types of multi-walled carbon nanotubes (MWCNT) to assess lung and pleural carcinogenicity, leading to analyses at 1 and 104 weeks post-exposure.
- - Results showed that while MWCNT exposure led to significant increases in lung tumors and oxidative DNA damage, FL and FLW did not induce carcinogenic effects in the
Lung carcinogenicity by whole body inhalation exposure to Anatase-type Nano-titanium Dioxide in rats.
J Toxicol Sci
August 2024
Japan Bioassay Research Center (JBRC), Japan Organization of Occupational Health and Safety.
Article Synopsis
- A study on the carcinogenicity of anatase-type nano-titanium dioxide (aNTiO) involved exposing F344/DuCrlCrlj rats to different aerosol concentrations for two years.
- The results showed that while bronchiolo-alveolar carcinomas appeared in two males exposed to the highest concentration, this finding was not significantly higher than historical control data.
- Non-cancerous lung lesions were noted, and the aNTiO levels in the lungs of rats decreased over time after exposure, leading to the conclusion of equivocal evidence for aNTiO's carcinogenicity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!